A STUDY ON ANTIBIOTIC SUSCEPTIBILITY PATTERN OF ESCHERICHIA COLI ISOLATES FROM EXTRA INTESTINAL INFECTIONS IN A TERTIARY CARE HOSPITAL.

N. Sudha, Dillirani V., Sheeba V., Fahad Affan and Hema
Department of Microbiology, Stanley Medical College, Chennai.-1,Tamil Nadu.

Abstract

Escherichia coli (E.coli), a common human intestinal commensal causes infections in bodily sites outside the gastrointestinal tract and are called Extra-intestinal pathogenic E.coli. ExPEC causes Urinary tract infections, Blood stream infections, Pneumonia, meningitis, bone, skin, and soft tissue infections including both nosocomial and community acquired infections. The increasing trend of developing antibiotic resistance in ExPEC is of global treat which causes increasing morbidity and mortality. As there is no vaccination for ExPEC so it is necessary to analyze the antibiotic susceptibility pattern for empirical treatment in emergency situations. Extended spectrum beta lactamases (ESBLs) hydrolyze β-lactam antibiotics of third generation Cephalosporins, Penicillins and Monobactams. Since the ESBL enzyme genes are usually found in large plasmids, they also contain other antimicrobial resistant genes. AmpC production in E.coli is through plasmids and mutation in their porin structure. Carbapenems are the drug of choice for ESBL producing Ecoli but recent time development of resistance is increasingly reported due to production of Carbapenemase. The aim of this study is to test the Antimicrobial susceptibility pattern of Extra-intestinal Ecoli isolates. The study was conducted in the department of Microbiology, Stanley Medical College, Chennai during the period October 2018 to May 2019. The institutional ethical committee approval was obtained and clinical samples such as urine, blood, pus, sputum and sterile body fluids were received from 983 patients suspected of bacterial infections. The samples were processed and biochemical test identified 84 Ecoli isolates. Antimicrobial testing, ESBL, AmpC screening and carbapenemase production were tested. E.coli isolates showed resistance to most of the beta lactam antibiotics such as Ampicillin, Cefotaxime and Ceftazidime and also to Ciprofloxacin & Cotrimoxazole.

Introduction:-

Escherichia coli (E.coli), a common human intestinal commensal causes infections in bodily sites outside the gastrointestinal tract and are called Extra-intestinal pathogenic E.coli (ExPEC). ExPEC causes Urinary tract infections, Blood stream infections, Pneumonia, Meningitis, bone, skin, and soft tissue infections including both nosocomial and community acquired infections. The increasing trend of developing antibiotic resistance in ExPEC is of global treat which causes increasing morbidity and mortality. As there is no vaccination for ExPEC so it is necessary to analyze the antibiotic susceptibility pattern for empirical treatment in emergency situations. Extended spectrum beta lactamases (ESBLs) hydrolyze β-lactam antibiotics of third generation Cephalosporins, Penicillins and Monobactams. Since the ESBL enzyme genes are usually found in large plasmids, they also contain other antimicrobial resistant genes. AmpC production in E.coli is through plasmids and mutation in their porin structure. Carbapenems are the drug of choice for ESBL producing Ecoli but recent time development of resistance is increasingly reported due to production of Carbapenemase. The aim of this study is to test the Antimicrobial susceptibility pattern of Extra-intestinal Ecoli isolates. The study was conducted in the department of Microbiology, Stanley Medical College, Chennai during the period October 2018 to May 2019. The institutional ethical committee approval was obtained and clinical samples such as urine, blood, pus, sputum and sterile body fluids were received from 983 patients suspected of bacterial infections. The samples were processed and biochemical test identified 84 Ecoli isolates. Antimicrobial testing, ESBL, AmpC screening and carbapenemase production were tested. E.coli isolates showed resistance to most of the beta lactam antibiotics such as Ampicillin, Cefotaxime and Ceftazidime and also to Ciprofloxacin & Cotrimoxazole.

Copy Right, IJAR, 2021. All rights reserved.
nosocomial and community acquired infections. It carries multiple virulence factors that enable to invade and colonize the extra intestinal sites.

The increasing trend of developing antibiotic resistance in ExPEC is of global treat causing morbidity and mortality. As there is no vaccination for ExPEC, it is necessary to analyze the antibiotic susceptibility pattern for empirical treatment in emergency situations. The mechanism of development of resistance is hydrolysis of antibiotics by Beta-lactamases enzymes produced by bacteria. Extended spectrum beta lactamases (ESBLs) hydrolyze beta-lactam antibiotics of third generation Cephalosporins, Penicillins and Monobactams. Since the ESBL enzyme genes are usually found in large plasmids, they also contain other antimicrobial resistant genes. Therefore ESBL producing organisms are also resistant to Aminoglycosides, Fluoroquinolones, chloramphenicol, and sulfonamides and are multi-drug resistant. ESBL E.coli resistant to Cephapemixin is classified as AmpC beta lactamases belong to class C Ambler classification and group1 by Bush-Jacob’s classification. AmpC production in E.coli is through plasmids and mutation in their porin structure. Carbapenem antibiotics are the drug of choice for ESBL producing E.coli but recent time development of resistance is increasingly reported due to production of Carbapenemase. The genes encoding for carbapenem production commonly detected are KPC, NDM, OXA, VIM, and IMP.

The aim of this study is to test the Antimicrobial susceptibility pattern of Extra-intestinal Ecoli isolates. This study was conducted in the department of Microbiology, Stanley Medical College, Chennai, during the period October 2018 to May 2019. The institutional ethical committee approval was obtained and clinical samples such as urine, blood, pus, sputum and sterile body fluids were received from 983 patients suspected of bacterial infection.

Materials and Methods:
The study was conducted in the department of Microbiology, Stanley Medical College, Chennai during the period October 2018 to May 2019. The institutional ethical committee approval was obtained and clinical samples such as urine, blood, pus, sputum and sterile body fluids were received from 983 patients suspected of bacterial infection. Processing of the sample including gram staining, motility testing and inoculating into Mac-Conkey agar plate, Blood agar plate and CLED in case of urine and incubating at 37°C for 18 to 24 hours were done. The culture showed positivity in 362 samples. Lactose fermenting, Motile, Gram negative bacilli, Catalase positive, oxidase negative, Indole test positive, citrate negative, urease negative, TSI: A/A with gas and absent H2S, Fermenting glucose, lactose, mannitol, maltose with gas and not fermenting sucrose, Methyl Red positive, VogesProskauer test negative were identified as Escherichia coli. This included 84Ecoli Isolates and Antimicrobial testing were done modified Kirby-Bauer disk diffusion method as a lawn culture on Mueller-Hinton agar the following drugs:- Ampicillin 10μg, Gentamicin 10μg, Amikacin 30μg, Amoxicillin-clavulanate 20/10 μg, Piperacillin-tazobactam 100/10μg, Cefotaxime 30μg, Cefazidime 30μg, Cefazolin 30μg (urinary isolates), Aztreonam 30μg, Ciprofloxacin 5μg, Levofloxacin 5μg, Trimethoprim-sulfamethoxazole 1.25/23.75 μg, Fosfomycin 200 μg (urinary isolates) and Nitrofurantoin 300 μg (urinary isolates), Turbidity was compared to a 0.5 MacFarland’s Turbidity. The control was prepared by using E coli ATCC 25922 strains and incubated at 37°C for 18 hours. Inner diameter of the zone of inhibition was measured by using a millimeter scale around each antimicrobial disk was interpreted as sensitive, intermediate or resistant according to the CLSI guidelines of 2018.

ESBL screening
The isolates that were resistant to Cefazidime (30μg) and Cefotaxime (30μg) by disc diffusion method with zones of inhibition of ≤ 22mm for Cefazidime and ≤ 27mm for Cefotaxime based on the CLSI 2018 guideline were considered as suspected ESBL producers.

Phenotypic Confirmatory Methods for Extended-Spectrum beta-Lactamases:
Double disk diffusion method was used to confirm ESBL production by E.coli strains. The test organisms inoculated by lawn culture onto Mueller Hinton agar plate. Cefazidime (30μg) disc vs. Cefazidime (30μg)/ Clavulanic acid (30/10μg) disc and Cefotaxime disc vs Cefotaxime/ clavulanic acid (30/10μg) disc were placed at least 20 mm apart, and incubated at 37°C for 18 hours. E.coli isolates demonstrating an increase in zone diameters of more than 5 mm either with Cefazidime / clavulanic or Cefotaxime-clavulanic-acid were ESBL producers.

Screening for Amp C beta lactamases:
The isolates were screened for AMPC production by testing their susceptibility to Cefoxitin (30μg) by Kirby Bauer disk diffusion method. All the isolates with an inhibition zone diameter < 18 mm were labeled as Amp C positive.
Confirmatory test for Amp C beta lactamases
Double disk diffusion method using Cefoxitin (30μg) and Cefoxitin (30μg) + Cloxacillin (200μg) combination were placed at a distance of 20mm on a Muller Hinton agar plate inoculated with test isolates. A zone diameter ≥ 4mm around the Cefoxitin+ Cloxacillin than the zone diameter around the Cefoxitin disc alone were considered as AmpC producers.

Test for Carbapenemase production
The isolates resistant to Carbapenem by disc diffusion method were screened for the production of Carbapenemase. The phenotypic detection of the Carbapenemase production was performed using mCIM and eCIM as per CLSI 2018 guidelines.

Modified Carbapenem inactivation Methods (mCIM)
For each isolate 1-μl loopful of pathogen was emulsified and vortexed for 10–15 sec. To this 10-μg Meropenem disk was added to each tube with a sterile forceps. The entire disk is immersed in the suspension. MRP disk was removed from each trypticase soy broth tube and placed on E. coli ATCC 25922 inoculated MHA and incubated.

EDTA Modified Carbapenem inactivation Methods
The same procedure is repeated after adding 20μl of the 0.5 M, EDTA to the 2-mL Trypticase soy broth tube. The MRP disks from the mCIM and eCIM tubes are placed on the same MHA plate, plated with the Meropenem-susceptible E.coli ATCC.

Results:-
Pie chart1:- Shows sample wise distribution of ExPEC isolates.

Out of the total 84 ExPEC isolates, 38 were from urine sample, 29 from pus, 6 from sputum and 11 from blood.
Table 1: Antibiotic Sensitivity of E.Coli isolated from various samples in percentage.

| Sample | Ampicillin | Gentamycin | Amikacin | Amoxicillin-clavulanic acid | Piperacillin-Tazobactum | Cefotaxime | Ciprofloxacin | Levofloxacin | Imipenem | Meropenem | Cotrimoxazole | Aztreonam | Cefazidime | Fosfomycin | Nitrofurantoin | Ceftazolin |
|--------|------------|------------|-----------|----------------------------|-------------------------|------------|---------------|--------------|-----------|-----------|----------------|-----------|------------|------------|----------------|-----------|
| N=84   |            |            |           |                            |                         |            |                |              |           |           |                |           |            |            |                |           |
| Urine% | 5          | 47         | 74        | 19                         | 76                      | 18         | 65             | 88           | 97        | 97        | 68             | 47        | 36         | 97         | 92             | 78        |
| n=38   |            |            |           |                            |                         |            |                |              |           |           |                |           |            |            |                |           |
| No of isolates | 2 | 18 | 28 | 7 | 28 | 7 | 24 | 33 | 37 | 37 | 26 | 18 | 14 | 37 | 35 | 30 |
| Pus n=29 | 6 | 62 | 72 | 41 | 86 | 6 | 14 | 86 | 96 | 93 | 10 | 14 | 10 | .... | .... | .... |
| No of isolates | 2 | 18 | 21 | 12 | 25 | 2 | 4 | 25 | 28 | 27 | 3 | 4 | 3 |       |       |       |
| Sputum %n=6 | 16 | 66 | 83 | 66 | 100 | 16 | 33 | 100 | 100 | 100 | 33 | 16 | 16 | .... | .... | .... |
| No of isolates | 1 | 4 | 5 | 4 | 6 | 1 | 2 | 6 | 6 | 6 | 2 | 1 | 1 |       |       |       |
| Blood% n=11 | 27 | 90 | 100 | 70 | 100 | 27 | 36 | 45 | 100 | 100 | 36 | 36 | 27 | .... | .... | .... |
| No of isolates | 3 | 10 | 11 | 7 | 11 | 3 | 4 | 5 | 11 | 11 | 4 | 4 | 3 |       |       |       |

Table 2: ESBL detection.

| ECOLI ISOLATES | ESBL by screening method | ESBL by double disc method | Percentage |
|----------------|--------------------------|-----------------------------|------------|
| Urine n=38    | 31                       | 20                          | 64%        |
| Pus n=29      | 4                        | 3                           | 75%        |
| Sputum n=6    | 5                        | 3                           | 60%        |
| Blood n=11    | 7                        | 5                           | 71%        |
| TOTAL         | 47                       | 31                          | 65%        |
Confirmatory test for ESBL by Double disc test

The Picture shows the detection of ESBL by Double disc test using Cefotaxime/ Cefotaxime+ Clavulanicacid and Ceftazidime/ Ceftazidime + clavulanic acid. There is an increase in zone diameter of inhibition of more than 5mm

ESBL detection by chrome agar

The picture shows growth of ESBLs producing magenta coloured EIPEC colonies in high chrome agar. All the 31 ESBL isolates detected by double disk test were found be positive in Hi-chrome agar.

Confirmatory test for Amp C beta lactamases Table 3

| ExPEC Isolates | Screening of AmpC producer by Cefoxitin disc diffusion | Amp C detection by Confirmatory test |
|----------------|-----------------------------------------------------|-------------------------------------|
| n= 73          |                                                     | Total | Percentage |
| Urine          | 18                                                  | 11    | 61         |
| Pus            | 13                                                  | 8     | 62         |
| Sputum         | 2                                                   | 1     | 50         |
| Blood          | 3                                                   | 2     | 66         |
| TOTAL          | 36                                                  | 22    | 61         |
Confirmatory test for Amp C beta lactamases

The picture shows AmpC confirmatory test using Cefoxitin and Cefoxitin+ Cloxacillin. There is an increase in zone diameter of inhibition of more than 4mm.

**Table 4:** Detection of Carbapenemase producers.

| S.No | Total Sample n =2 | Screening of Carbapenem resistant by disk diffusion testing | Modified Carbapenem inactivation Methods |
|------|-------------------|-----------------------------------------------------------|----------------------------------------|
|      |                   |                                                           | mCIM | eCIM |
| 1    | Pus               | 1                                                         | 1    | 0    |
| 2    | Urine             | 1                                                         | 1    | 0    |
| 3    | Sputum            | 0                                                         | 0    | 0    |
| 4    | Blood             | 1                                                         | 1    | 0    |
|      | Total             | 3                                                         | 3    | 0    |

Shows Carbapenem resistance: - one isolate from pus and one isolate from urine

**Modified Carbapenem Inactivation Methods for Suspected Carbapenemase Production mCIM and eCIM**

Shows Positive mCIM and Negative eCIM

**Discussion:**
Isolates with antibiotic resistance are responsible for treatment failure among infected patients. In this study Extraintestinal E.coli isolates showed resistance to most of the beta lactam antibiotics such as Ampicillin,
Cefotaxime and Ceftazidime and also to Ciprofloxacin & Cotrimoxazole, pattern of various ExPEC isolates were analyzed. A total of 84 ExPEC isolates consisting of 38 isolates from urine, 29 isolates from pus, 6 isolates from sputum and 11 isolates from blood were subjected to antimicrobial testing. It was observed that extra consistent with previous study by Asima Banu et al.

Among the 84 ExPEC isolates tested, 47 isolates were identified to be resistant to Ceftazidime and Cefotaxime as per ESBL-CLSI 2018 screening test. Of these 22 (30%) isolates were detected to be ESBLs by Double disc test.

Of the 84 isolates, 22 were positive for Amp C beta lactamases by screening test, of these 18 isolate were confirmed AmpC by double disc test. Compared to the study by Sara shayan et al, which showed ESBL producers of 62% and AmpC producer of 5%, but this study shows an increase in AmpC producers as shown in table 2 and 3. This study revealed 2(2.7%) Carbapenemase producers among extra intestinal E.coli isolates, consistent with the previous study by Rituparna Tewari.

It is found that most of the beta lactamase producers were also resistant to other groups of antibiotics such as Quinolones and Sulphonamides as shown in table: 1. This is in accordance with the previous study by Asima Banu et al. This can be attributed to ESBL genes that are usually found in large plasmids also contain other antimicrobial resistant genes. Multi drug resistance isolates were 32 (41%). This is comparatively less than to the incidence of 50 % MDR shown in a study by Amhed on ExPEC 2016.

It is noted in chart 4, there is a relatively high antibiotic resistance among the sample received from hospitalized patients compared to outpatients similar to study by Asima Banu et al. The antibiotic resistance among hospitalized patients could be explained because of empirical treatment with multiple antibiotics. But in urinary isolates of extra intestinal E.coli, there was high resistance in outpatients similar to study by Asima Banu, et al.

Conclusion:
The early detection of resistant strains of ExPEC plays a vital role in reduction of morbidity and mortality. Judicious use of antibiotics and a good antibiotic policy are needed to limit the emergence and spread of antibiotic resistance in bacteria. The appropriate selection of antibiotics for the treatment depends on the early and prompt antibiotic sensitivity test. Empirical treatment of antibiotics prior to antibiotic sensitivity report should be avoided unless indicated. Good hand hygiene practices, Health education of healthcare personnel, professionals, contact precautions and minimal use of interventional devices would prevent spread of nosocomial resistant strains.

Conflict of interest:
None.

1. Asima Banu, Jyoti S Kabbin, Mridu Anand “Extraintestinal Infections due to Escherichia Coli: An Emerging Issue “Journal of Clinical and Diagnostic Research. 2011 June
2. Jannatul Ferdous1, Taslima Begum1, Taslima Akter1, Mohammad Murshed1, Noor Jahan2, Sabeena Shahnaz1 “Study of Extra intestinal E.coli and their resistant pattern in a tertiary care hospital of Bangladesh” Bangladesh J Med Microbiol 2017
3. Sudheendra Ramesh Kulkarni, Basavaraj V. Peerapur,1 and Kumar Sai Sailesh2 “Isolation and Antibiotic Susceptibility Pattern of Escherichia coli from Urinary Tract Infections in a Tertiary Care Hospital of North Eastern Karnataka” J Nat SciBiol Med. 2017 Jul-Dec.
4. Fakruddin M, Mazumdar RM, Chowdhury A, Mannan KS “A preliminary study on virulence factors & antimicrobial resistance in extra-intestinal pathogenic Escherichia coli (ExPEC) in Bangladesh”. Indian J Med Res. 2013 May;
5. Rituparna Tewari1,2, Susweta D. Mitra1,3, Feroze Ganaee1, Nimita Venugopal1,2, Sangita Das1, Rajeswari Shome1, Habibur Rahman1, Bibeck R. Shome1 “Prevalence of extended spectrum β-lactamase, AmpC β-lactamase and metallo β-lactamase mediated resistance in Escherichia coli from diagnostic and tertiary healthcare centers in south Bangalore, India” Int J Res Med Sci. 2018 April.
6. Gary W. Procop, Deirdre L.Geraldine S. Hall, William M. Janda, Elmer W. Koneman, Paul C. Schreckenberger Gail L. Woods – Church “Koneman’s Color Atlas and Text book of Microbiology”
7. Mahalingam N., Manivannan B., Siddaramappa S., Adak S. “Detection of Antibiotic Resistance Determinants and Their Transmissibility among Clinically Isolated Carbapenem-Resistant Escherichia coli from South India”. November 2018 Medical Principles and Practice.
8. Christel Dagher, Tamara Salloum, Sahar Alousi, Harout Arabaghian, George F. Araj, Sima Tokajia “Molecular characterization of Carbapenem resistant *Escherichia coli* recovered from a tertiary hospital in Lebanon’ September 6, 2018 plos one
9. Antimicrobial resistance and its containment in India-WHO guidelines-2016.
10. Ida orskov and frits orskov International Escherichia and Klebsiella Centre (WHO), Statens Serum Institut, Copenhagen, Denmark “Escherichia coli in extra-intestinal infections”.
11. Olivier Clermont, Stéphane Bonacorsi, and Edouard Bingen “Rapid and Simple Determination of the *Escherichia coli* Phylogenetic Group”.
12. Chinakakani, Guntur, Andhra Pradesh, South India Anuradha Bhrugubalda, Uma Penmetcha, Padmaja Yarlagadda and Ramesh Babu Myeneni. “A Study of Virulence Factors and Drug Resistance Pattern in *Escherichia coli* Isolated from Extra Intestinal Infections in a Tertiary Care Teaching Hospital”;
13. Lenka Micenková, Juraj Bosák, Martin Vrba, Alena Sevcikova and David Smajs. “Extra intestinal Pathogenic *Escherichia coli*, a Common Human Pathogen Human extraintestinal pathogenic *Escherichia coli* strains differ in prevalence of virulence factors, phylogroups, and bacteriocin determinants.”
14. Ndapewa Laudika Ithete, Samantha Stoffberg, Victor Max Corman, Veronika M. Cottontail, Leigh Rosanne Richards, M. Corrie Schoeman, Christian Drosten, Jan Felix Drexler, and Wolfgang Preiser. “Multi-drug-Resistant *Escherichia coli* Bacteremia”;
15. Manju Raj Purohit, Salesh Chandran, Harshada Shah, Vishal Diwan, Ashok J. Tamhankar, I. and Cecilia Stålsby Lundborg. “Antibiotic Resistance in an Indian Rural Community: A ‘One-Health’ Observational Study on Commensal Coliform from Humans, Animals, and Water.”
16. Felix Oluwasola, Olorunmola 1, Deboye Oriade, Kolawole 2, and Adebayo Lamikanra 3 “Antibiotic resistance and virulence properties in *Escherichia coli* strains from cases of urinary tract infections”.
17. Antimicrobial resistance in India Isha Patel, Rabia Hussain, Anam Khan, Akram Ahmad, Muhammad Umair Khan, and Mohamed Azmi Ahmed. “Detection of ESBL- and AmpC-producing *E. coli* isolates from urinary tract infections”.
18. Shayan S, Bokaeian M, Shahraki S. “Role of *fimH* in extraintestinal pathogenic *Escherichia coli* Invasion and translocation through the intestinal epithelium”. 2017.